Figure 5. Role of FPR2/ALX signaling in anti-inflammatory effects of OxPAPC and LXA4.
Cells were treated with TNFα (20 ng/ml) alone or pretreated with OxPAPC (15 μg/ml) or LXA4 (100 nM) for 30 min. A - Effect of FPR2/ALX inhibitor WRW4 on IκBα degradation, ICAM1 and VCAM1 expression. Probing for β-tubulin was used as a normalization control. B - Effect of siRNA-induced FPR2/ALX knockdown on VCAM1 expression. Numerical data depict results of quantitative densitometry; n=3; * p<0.05. C - Effect of FPR2/ALX inhibitor on sICAM1 release in culture medium evaluated by ELISA assay; n=5, *P < 0.05.